Pharnext (FR:ALPHA) has released an update.
Pharnext SCA, a biopharmaceutical company focused on neurodegenerative diseases, has announced a capital reduction due to losses by decreasing the nominal value of its shares. The reduction is from 0.01 euro to 0.0002 euro per share, with a warn to investors about potential losses and dilution from rapid market sales and dilutive financing operations. Pharnext urges investors to exercise caution when investing in their securities.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
